$BLRX News

BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript

BioLine Rx Q1 Sales $477.000K Beat $343.000K Estimate

BioLineRx And Hemispherian Announce Two Abstracts Featuring GLIX1 Will Be Published At ASCO 2026 Annual Meeting

BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models

BioLineRx Announces New Preclinical Data That Further Support The Recently Initiated Phase 1/2a Clinical Trial Evaluating GLIX1 For Recurrent And Progressive GBM And Other High-Grade Gliomas

BioLineRx shares are trading higher after the company announces that the first patient has been dosed in its Phase 1/2A study of GLIX-1 for glioblastoma and other high-grade gliomas.

BioLineRx Announces That The First Patient Has Been Dosed In Its Phase 1/2A Study Of GLIX-1 For The Treatment Of Recurrent And Progressive Glioblastoma And Other High-Grade Gliomas

BioLineRx Launches First Human Trial For Brain Cancer Drug

BioLine Rx Q4 EPADS $(0.34) Beats $(0.54) Estimate, Sales $194.000K Miss $651.598K Estimate

BioLineRx Ltd. (BLRX) Q4 2025 Earnings Call Transcript

BioLine Rx Q4 Sales $194.000K Miss $651.598K Estimate

Top Wall Street Forecasters Revamp BioLineRx Expectations Ahead Of Q4 Earnings

Arbitrator Issues Final Award To BioLineRx, Denies All Claims By Biokine Therapeutics; Biokine To Pay Expenses And Legal Fees

BioLine Rx Ltd (BLRX) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...

BLRX: Stem Cell Mobilization Presentation at ASH

BioLine Rx Q3 EPADS $(0.22) Beats $(1.20) Estimate, Sales $427.000K Miss $990.000K Estimate

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx Ltd. (BLRX) Q3 2025 Earnings Call Transcript

BioLine Rx's Earnings: A Preview

Hemispherian And BioLineRx Secure USPTO Notice Of Allowance For GLIX1 With Protection Extending To 2040